

## Brief Report

# Transcription Factor 7-Like 2 (*TCF7L2*) Is Associated With Gestational Diabetes Mellitus and Interacts With Adiposity to Alter Insulin Secretion in Mexican Americans

Richard M. Watanabe,<sup>1,2</sup> Hooman Allayee,<sup>1,3</sup> Anny H. Xiang,<sup>1</sup> Enrique Trigo,<sup>4</sup> Jaana Hartiala,<sup>3</sup> Jean M. Lawrence,<sup>5</sup> and Thomas A. Buchanan<sup>2,4</sup>

**OBJECTIVE**—Variation in transcription factor 7-like 2 (*TCF7L2*) gene has been shown to be associated with type 2 diabetes and diabetes-related quantitative traits. We examined variation in a 0.1-Mb region surrounding marker DG10S478 for association with diabetes-related quantitative traits in 132 Mexican-American families of a proband with previous gestational diabetes mellitus (GDM).

**RESEARCH DESIGN AND METHODS**—Study participants were phenotyped by an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test and by a dual-energy X-ray absorptiometry scan for percentage of body fat. Of the 42 tag single nucleotide polymorphisms (SNPs) genotyped, 15 were identified.

**RESULTS**—On univariate analysis, none of the SNPs showed association with diabetes-related quantitative traits. However, rs12255372 showed association with 30'  $\Delta$ insulin (OGTT 30' min fasting insulin) in an interaction with percentage of body fat (Bonferroni-corrected  $P = 0.027$ ). The effect of adiposity to increase 30'  $\Delta$ insulin was greater in subjects with the T allele. This interaction was not associated with acute insulin response to intravenous glucose. rs12255372 also showed an association with  $\beta$ -cell compensation for insulin resistance based on 30'  $\Delta$ insulin in an interaction with percentage of body fat (Bonferroni-corrected  $P = 0.014$ ). rs12255372 was also associated with GDM (odds ratio [OR] 2.49 [95% CI 1.17–5.31];  $P = 0.018$ ) in our case-control sample.

From the <sup>1</sup>Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, the University of Southern California, Los Angeles, California; the <sup>2</sup>Department of Physiology and Biophysics, Keck School of Medicine, the University of Southern California, Los Angeles, California; the <sup>3</sup>Institute for Genetic Medicine, Keck School of Medicine, the University of Southern California, Los Angeles, California; the <sup>4</sup>Division of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine, the University of Southern California, Los Angeles, California; and <sup>5</sup>Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.

Address correspondence and reprint requests to Richard M. Watanabe, PhD, Department of Preventive Medicine, Keck School of Medicine of USC, 1540 Alcazar St., CHP-220, Los Angeles, CA 90089-9011. E-mail: rwatanab@usc.edu.

Received for publication 1 December 2006 and accepted in revised form 9 February 2007.

Published ahead of print at <http://diabetes.diabetesjournals.org> on 22 February 2007. DOI: 10.2337/db06-1682.

Additional information for this article can be found in an online appendix at <http://dx.doi.org/10.2337/db06-1682>.

AIR, acute insulin response; GDM, gestational diabetes mellitus; IVGTT, intravenous glucose tolerance test; LD, linkage disequilibrium; OGTT, oral glucose tolerance test.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**CONCLUSIONS**—We conclude that variation in *TCF7L2* is associated with GDM and interacts with adiposity to alter insulin secretion in Mexican Americans. Our observations partly explain the increased ORs observed in previous associated studies when analyses were restricted to lean subjects and the variability in quantitative trait association results. *Diabetes* 56:1481–1485, 2007

Variation in transcription factor 7-like 2 (*TCF7L2*) gene was first shown to be associated with type 2 diabetes in the Icelandic population (1) and replicated in a variety of populations (2–8) with some reporting association with type 2 diabetes-related quantitative traits (2,6,7). Thus, there is ample evidence supporting *TCF7L2* as a type 2 diabetes susceptibility gene, possibly by altering insulin secretion. However, evidence for *TCF7L2*'s association with type 2 diabetes is mostly derived from Caucasian samples, and its role in other ethnic/racial groups or other forms of diabetes has not been delineated.

Mexican-American women with previous gestational diabetes mellitus (GDM) exhibit significant  $\beta$ -cell dysfunction and are at high risk for type 2 diabetes (9). The BetaGene Study is a family-based study to identify genetic determinants underlying differences in  $\beta$ -cell function in Mexican Americans. We examined genetic variation in a 0.1-Mb region surrounding DG10S478 (1) and tested variants for association with type 2 diabetes-related quantitative traits in our BetaGene cohort. We also tested whether the association between *TCF7L2* and type 2 diabetes-related quantitative traits is modified by adiposity, given some suggestion that *TCF7L2* variants may interact with adiposity to modify the risk of type 2 diabetes (6,8).

## RESEARCH DESIGN AND METHODS

**Subject recruitment.** Subject recruitment for the BetaGene Study is ongoing, and for this report we describe only those clinical protocols and assays relevant to the results presented herein. Participation in the BetaGene Study is restricted to Mexican Americans from families of a proband with previous GDM. Details regarding subject recruitment can be found in the supplemental materials (located in an online appendix at <http://dx.doi.org/10.2337/db06-1682>). In addition, we are recruiting Mexican-American women who have gone through pregnancy without GDM but are also selected to be age-, BMI-, and parity-matched to the GDM probands. For the present report, we performed the relevant genotyping and data analysis on all control subjects, GDM probands, siblings, and cousins who had been phenotyped by the end of November 2005. All protocols for the

TABLE 1  
Tag SNP characteristics

SNP	Position (kb)*	Minor allele	Minor allele frequency	SNPs tagged
rs7901695†	114744078	C	0.24	rs7903146†
rs7896811	114756707	T	0.07	
				rs6585202, rs7077247, rs11196208, rs6585200, rs10885405, rs10885409, rs11196205†, rs7895340†, rs12265291, rs7924080
rs7100927	114786038	G	0.28	rs12243326 rs11196213, rs7085989  rs911769 rs12768310, rs3750804
rs11196203	114795850	A	0.08	
rs12255372†	114798892	T	0.19	
rs7087006	114813416	G	0.26	
rs10885410	114814463	A	0.20	
rs7919409	114814966	C	0.21	
rs7100388	114815803	G	0.09	
rs7908486	114824488	G	0.37	
rs11196218	114830484	A	0.23	
rs7082458	114836639	G	0.10	
rs3814572	114837713	G	0.07	
rs10749127	114839343	T	0.29	
rs4639863	114844373	T	0.32	

\*Based on NCBI build 36.1. †Previously reported by Grant et al. (1).

BetaGene Study have been approved by the institutional review boards of the participating institutions.

**Clinical protocols.** Phenotyping is performed on two separate visits to the University of Southern California General Clinical Research Center. Visit 1 consists of a physical examination, DNA collection, and a 75-g 2-h oral glucose tolerance test (OGTT) with 30-min blood sampling. Participants with fasting glucose <126 mg/dl are invited for a second visit, which consists of a dual-energy X-ray absorptiometry scan for determination of percentage of body fat and an insulin-modified intravenous glucose tolerance test (IVGTT).

**Molecular analysis.** Single nucleotide polymorphisms (SNPs) in all four HapMap (release no. 19) populations were, whenever possible, selected at ~2.5-kb intervals across a 0.1-Mb region surrounding DG10S478. Forty-two SNPs were selected and genotyped using the Applied Biosystems TaqMan system (10).

**Data analysis.** We calculated two measures of insulin response to glucose; the difference between the 30' and fasting plasma insulin concentrations from the OGTT (30' Δinsulin) and the incremental area under the insulin curve for the first 10 min of the IVGTT (acute insulin response [AIR]). IVGTT glucose and insulin data were analyzed by minimal model (MINMOD Millennium version 5.18). The disposition index (DI), a measure of β-cell compensation for insulin resistance, was computed as the product of the insulin sensitivity index (S<sub>I</sub>) and early insulin response (DI = S<sub>I</sub> × AIR from the IVGTT [11,12]; DI<sub>30</sub> = S<sub>I</sub> × 30 min Δinsulin from the OGTT [13]).

Genotype data were tested for deviation from the Hardy-Weinberg equilibrium and for non-Mendelian inheritance using PEDSTATS version 0.6.4 (14),

and allele frequencies were estimated using SOLAR version 2.1.4 (15). Tagging SNPs were selected from among the genotyped SNPs using TAGGER as implemented in Haploview version 3.32 (16,17). Linkage disequilibrium (LD) and haplotype block structure were also assessed using Haploview (18). The measured genotypes approach under a variance components and a likelihood ratio framework was used to test SNP associations with continuous phenotypes and implemented using SOLAR (15) with ascertainment correction.

Each SNP was first tested for a trend for association with quantitative traits under an additive genetic model. The reference allele was the minor allele, and models were adjusted for age, sex, and, where appropriate, percentage of body fat. A significant trend was defined as a nominal *P* value of 0.1, corrected for the number of SNPs tested (*n* = 15; *P* = 0.0067). SNPs showing a trend were then tested for association under dominant and/or recessive genetic models. SNPs significantly associated with any type 2 diabetes-related quantitative trait were also tested for a multiplicative interaction with percentage of body fat. The three SNPs that tagged previously associated SNPs (rs7901695, rs7100927, and rs12255372; Table 1) were tested for an interaction with adiposity regardless of their univariate association results.

Linear modeling results are reported as age-, sex-, and percentage of body fat-adjusted medians and interquartile ranges. For results from the interaction analysis that included percentage of body fat, trait values are reported as age- and sex-adjusted medians and interquartile ranges. In all cases, reported *P* values are Bonferroni corrected for multiple comparisons unless otherwise specified.

TABLE 2  
Subject characteristics

	GDM probands	Siblings	Cousins	Control subjects
<i>n</i>	94	241	179	58
Male/female	0/94	88/153	80/99	0/58
Age (years)	35.0 (8.6)	34.5 (11.0)	32.8 (11.8)	33.4 (7.6)
BMI (kg/m <sup>2</sup> )	30.9 (8.9)	29.1 (6.3)	27.4 (6.6)	27.2 (6.6)
Body fat (%)	39.1 (7.3)	33.5 (13.9)	30.7 (12.8)	36.0 (7.0)
Fasting glucose (mmol/l)	5.4 (0.9)	5.1 (0.6)	5.1 (0.6)	4.9 (0.4)
2-h glucose (mmol/l)	8.4 (3.4)	7.3 (2.6)	6.4 (2.2)	6.9 (2.1)
Fasting insulin (pmol/l)	69 (48)	42 (42)	36 (36)	30 (36)
2-h insulin (pmol/l)	522 (462)	372 (378)	300 (336)	252 (312)
30' Δinsulin (pmol/l)	372 (252)	321 (252)	366 (342)	294 (324)
S <sub>G</sub> (×10 <sup>-2</sup> per min <sup>-1</sup> )	1.29 (0.41)	1.55 (0.71)	1.74 (0.88)	1.84 (0.94)
S <sub>I</sub> (×10 <sup>-3</sup> per min <sup>-1</sup> per pmol/l)	3.63 (2.06)	4.32 (3.28)	4.85 (3.17)	5.67 (3.01)
AIR (pmol/l × 10 min)	1,990 (2,648)	2,572 (2,788)	3,044 (3,610)	2,974 (2,348)
DI	780 (780)	1,141 (1,145)	1,339 (1,106)	1,714 (972)

Data are unadjusted median (interquartile range) unless otherwise indicated.




FIG. 1. *TCF7L2* pairwise LD structure. Pairwise LD and haplotype block structure as determined by the method of Gabriel for the 40 SNPs genotyped in our Mexican-American families. LD is displayed as pairwise  $r^2$  values (values within boxes), where white indicates  $r^2 = 0$ , varying shades of gray indicate  $0 < r^2 < 1$ , and black indicates  $r^2 = 1$ .

## RESULTS

We report results from 537 individuals in 132 families (Table 2). Control subjects were slightly younger and less obese compared with GDM probands, reflecting recruitment of control subjects lagging slightly behind GDM


probands to allow for matching as described above. Pairwise LD and haplotype blocks (Fig. 1) were estimated using 40 of 42 genotyped SNPs (rs7904519 and rs7907632 failed Hardy-Weinberg equilibrium), resulting in a density of  $\sim 2.57$  kb. Seven haplotype blocks were identified. The largest block included three previously associated SNPs (rs7895340, rs1196205, and rs12255372) (1), and two other previously associated SNPs (rs7901695 and rs7903146) (1) formed an independent block. Table 2 shows the characteristics of the 15 tag SNPs. None of the tag SNPs showed a trend for association with quantitative traits under an additive genetic model; the two strongest associations were with traits related to insulin secretion: rs10885410 was associated with 30'  $\Delta$ insulin (uncorrected  $P = 0.010$ ), and rs11196218 was associated with AIR (uncorrected  $P = 0.008$ ).

We then tested whether previously associated SNPs (rs7100927, rs7901695, and rs12255372) interacted with adiposity to alter variation in quantitative traits. rs12255372 under an additive genetic model showed a significant interaction with percentage of body fat to alter 30'  $\Delta$ insulin (uncorrected  $P = 0.009$ ), and rs7901695 interacted with percentage of body fat to alter  $S_1$  (uncorrected  $P = 0.027$ ). Only the interaction with rs12255372 remained significant after correcting for multiple comparisons. The interaction remained significant, assuming a dominant genetic model ( $P = 0.016$ ). The interaction between rs12255372 and adiposity was not associated with AIR or  $S_1$  and showed marginal association with fasting insulin (uncorrected  $P = 0.157$ ,  $P = 0.744$ , and  $P = 0.067$ , respectively).

We stratified 30'  $\Delta$ insulin by rs12255372 genotype assuming a dominant genetic model and by percentage of body fat tertiles within each genotype group (Fig. 2). 30'  $\Delta$ insulin increases with increasing adiposity, with the effect stronger among individuals with a T allele (Fig. 2A). The model-predicted 30'  $\Delta$ insulin concentration (Fig. 2B) revealed that within the range of percentage of body fat up to  $\sim 34\%$ , subjects with a T allele had lower 30'  $\Delta$ insulin, whereas they had higher 30'  $\Delta$ insulin in the higher percentage of body fat range when compared with G homozygotes.

Examination of the covariate-adjusted, genotype-specific median  $S_1$  for rs12255372 stratified by percentage of body fat tertiles revealed a pattern of increasing insulin resistance with adiposity regardless of genotype (data not shown). Such differences in  $S_1$  could confound patterns in 30'  $\Delta$ insulin, which changes reciprocally with changes in  $S_1$  (11,12). Therefore, we tested whether an index of  $\beta$ -cell compensation based on the 30'  $\Delta$ insulin ( $DI_{30} = S_1 \times 30'$   $\Delta$ insulin) was associated with the interaction between rs12255372 and adiposity. Assuming a dominant genetic model, the interaction was significantly associated with  $DI_{30}$  ( $P = 0.014$ ). Increasing adiposity had a modest modifying effect on  $DI_{30}$  among individuals with a T allele but a dramatic effect in reducing  $DI_{30}$  among G homozygotes (Fig. 3A). The model-predicted  $DI_{30}$  (Fig. 3B) shows that at low percentages of body fat,  $DI_{30}$  was higher in G homozygotes than those with a T allele.  $DI_{30}$  fell with increasing percentages of body fat in both groups, but the fall was less steep in individuals with a T allele.  $DI$  from IVGTTs was not associated with the interaction between rs12255372 and percentage of body fat (uncorrected  $P = 0.152$ ).

Given the trait associations, we tested rs12255372 for association with previous GDM. The frequency of the T allele among probands with previous GDM ( $n = 94$ ) was 39.4% compared with 20.7% in control subjects without




**FIG. 2.** Interaction between rs12255372 and percentage of body fat on 30' Δinsulin concentrations. **A:** Median age- and sex-adjusted 30' Δinsulin concentration and interquartile range stratified by genotype and percentage of body fat tertiles. Within the lowest body fat tertile, individuals homozygous for the G allele have higher adjusted 30' Δinsulin compared with individuals with at least one copy of the T allele. However, within the highest body fat tertile, individuals homozygous for the G allele have lower adjusted 30' Δinsulin concentrations. The effect of adiposity to alter 30' Δinsulin is greater among subjects with a T allele compared with those homozygous for the G allele. **B:** Interaction based on the model parameter estimates and covering the range of body fat observed in the BetaGene Study.

previous GDM ( $n = 58$ ). The association, assuming a dominant genetic model, was significant (odds ratio [OR] 2.49 [95% CI 1.17–5.31];  $P = 0.018$ ) and remained significant when adjusting for age and percentage of body fat (2.62 [1.13–6.11];  $P = 0.025$ ). rs7901695 and rs7100927 showed no evidence for association with GDM ( $P = 0.601$  and  $P = 0.627$ , respectively).

## DISCUSSION

There are two novel findings from this study. First, rs12255372 in *TCF7L2* was significantly associated with GDM under a dominant genetic model. This is the first evidence that *TCF7L2* is associated with forms of prediabetes. We did not genotype ancestrally informative markers, so it is possible that population substructure may confound our results. However, given that the identical marker also shows association with type 2 diabetes-related quantitative traits, it is likely that this is a true association with GDM.

Second, rs12255372 was associated with 30' Δinsulin in



**FIG. 3.** Interaction between rs12255372 and percentage of body fat on β-cell compensation, computed as the product of  $S_i \times 30'$  Δinsulin concentration (DI30). **A:** Median age- and sex-adjusted DI30 and interquartile range stratified by genotype and percentage of body fat tertiles. Within the lowest body fat tertile, individuals homozygous for the G allele have higher adjusted DI30 compared with individuals with at least one copy of the T allele. However, within the highest body fat tertile, individuals homozygous for the G allele have lower adjusted DI30. The effect of adiposity to alter DI30 is greater among subjects homozygous for the G allele compared with those with at least one copy of the T allele. **B:** Interaction based on the model parameter estimates and covering the range of body fat observed in the BetaGene Study.

an interaction with percentage of body fat. This finding could explain some of the inconsistencies in association between *TCF7L2* and quantitative traits among studies. It may also explain the increased OR for association with type 2 diabetes (1.89 vs. 1.69) reported by Cauchi et al. (8) when their analysis was restricted to lean subjects (BMI <30 kg/m<sup>2</sup>). The lack of association between this interaction and AIR from the IVGTT is consistent with an effect mediated through an enteroendocrine mechanism (e.g., glucagon-like peptide 1), as proposed by Grant et al. (1).

Since insulin secretion normally varies as a function of insulin resistance (11,12), associations with insulin secretion could simply reflect an underlying difference in insulin resistance to which β-cells are responding. Two lines of evidence argue against this. First, the interaction between adiposity and rs12255372 was not associated with  $S_i$ . Second, the interaction was associated with DI30, which tended to be relatively low in lean individuals with a T allele but to fall relatively little with increasing adiposity compared with G homozygotes. The biological signifi-

cance of this finding in relation to diabetes risk remains to be determined, but  $\beta$ -cell compensation at any point in time reflects dual influences of acute regulatory stimuli and cumulative effects of chronic factors such as insulin resistance. We have reported that chronic insulin resistance and high levels of insulin secretion may be detrimental to long-term  $\beta$ -cell compensation (19,20). It is possible that *TCF7L2* variants have dual effects, limiting  $\beta$ -cell compensation for insulin resistance at any given time through acute effects (e.g., incretins) but minimizing deterioration of insulin secretion related to obesity and insulin resistance over time. This mechanism would be analogous to the effects of *MODY2* variants, where glucose levels are elevated but tend not to deteriorate over time, unlike most forms of diabetes (A. Hattersley, personal communication).

It is noteworthy that many reports for *TCF7L2* association with type 2 diabetes come from Caucasian populations in whom rs7901695 is in moderate to strong LD ( $r^2 > 0.7$ ) with rs12255372 and partly accounts for why both SNPs show association with type 2 diabetes (1,3–6,8), although other Caucasian populations report weaker LD between these SNPs (2), and there is a near absence of LD in African Americans (6). However, in our Mexican-American population, both were in relatively low LD ( $r^2 = 0.55$ ), resulting in their selection as tag SNPs. This may account for why the interaction between rs7901695 and percentage of body fat was not associated with type 2 diabetes-related quantitative traits and suggests that other functional variants of *TCF7L2* may be distal to rs7901695.

In summary, we observed a strong association between *TCF7L2* rs12255372 and GDM, along with an interaction between rs12255372 and adiposity to alter insulin secretion in Mexican Americans from families with GDM. The interaction with adiposity led to relatively poorer  $\beta$ -cell compensation in relatively lean individuals but better preservation of compensation with increasing adiposity. This pattern could explain prior observations that relative risks of type 2 diabetes associated with variants in *TCF7L2* are highest in relatively lean individuals. The observed interaction also suggests a dual role of rs12255372 to downregulate acute  $\beta$ -cell compensation but limit the impact of obesity and chronic insulin resistance to damage  $\beta$ -cells and their function.

#### ACKNOWLEDGMENTS

This work was supported by National Institutes of Health Grant DK-61628 and an American Diabetes Association Distinguished Clinical Scientist Award to T.A.B. A portion of this work was conducted in a facility constructed with support from Research Facilities Improvement Program Grants C06 (RR10600-01, CA62528-01, and RR14514-01) from the National Center for Research Resources.

We thank the families who participated in the BetaGene Study and the support of the University of Southern California General Clinical Research Center (M01-RR-00043). We also acknowledge the efforts of our recruiting and technical staff.

#### REFERENCES

- Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadóttir A, Styrkarsdóttir U, Magnusson KP, Walters GB, Palsdóttir E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdóttir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription

- factor 7-like 2 (*TCF7L2*) gene confers risk of type 2 diabetes. *Nat Genet* 38:320–323, 2006
- Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD, and Shuldiner AR: Polymorphisms in the transcription factor 7-like 2 (*TCF7L2*) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. *Diabetes* 55:2654–2659, 2006
- Scott LJ, Bonycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR, Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Collins FS, Boehnke M: Association of transcription factor 7-like 2 (*TCF7L2*) variants with type 2 diabetes in a Finnish sample. *Diabetes* 55:2649–2653, 2006
- Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, Hitman GA, Walker M, Wiltshire S, Hattersley AT, McCarthy MI: Association analysis of 6,736 U.K. subjects provides replication and confirms *TCF7L2* as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. *Diabetes* 55:2640–2644, 2006
- Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, and Hu FB: Variant of transcription factor 7-like 2 (*TCF7L2*) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. *Diabetes* 55:2645–2648, 2006
- Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM, Altschuler D, the Diabetes Prevention Program Research Group: *TCF7L2* polymorphisms and progression to diabetes in the diabetes prevention program. *N Engl J Med* 355:242–250, 2006
- Saxena R, Gianniny L, Burt NP, Lyssenko V, Giuducchi C, Sjögren M, Florez JC, Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ, Tuomi T, Hirschhorn JN, Ardlie KG, Groop LC, Altschuler D: Common single nucleotide polymorphisms in *TCF7L2* are reproducibly associated with type 2 diabetes and reduced insulin response to glucose in nondiabetic individuals. *Diabetes* 55:2890–2895, 2006
- Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Frühbeck G, Froguel P: Transcription factor *TCF7L2* genetic study in the French population: expression in human  $\beta$ -cells and adipose tissue and strong association with type 2 diabetes. *Diabetes* 55:2903–2908, 2006
- Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes. *Diabetes Care* 25:1862–1868, 2002
- Livak KJ: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. *Genet Anal* 14:143–149, 1999
- Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and  $\beta$ -cell glucose sensitivity from the response to intravenous glucose. *J Clin Invest* 68:1456–1467, 1981
- Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and  $\beta$ -cell function in human subjects: evidence for a hyperbolic function. *Diabetes* 42:1663–1672, 1993
- Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP: Response of pancreatic  $\beta$ -cells to improved insulin sensitivity in women at high risk for type 2 diabetes. *Diabetes* 49:782–788, 2000
- Wigginton JE, Abecasis GR: PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. *Bioinformatics* 21:3445–3447, 2005
- Almasy L, Blangero J: Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet* 62:1198–1211, 1998
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: Analysis and visualization of LD and haplotype maps. *Bioinformatics* 21:263–265, 2005
- de Bakker PIW, Yelensky R, Pe'er D, Gabriel SB, Daly MJ, Altschuler D: Efficiency and power in genetic association studies. *Nat Genet* 37:1217–1223, 2005
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altschuler D: The structure of haplotype blocks in the human genome. *Science* 296:2225–2229, 2002
- Peters RK, Kjos SL, Xiang A, Buchanan TA: Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. *Lancet* 347:227–230, 1996
- Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA: Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes. *Diabetes* 48:848–854, 1999
- Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK: Antepartum predictors of the development of type 2 diabetes in Latino women 11–26 months after pregnancies complicated by gestational diabetes. *Diabetes* 48:2430–2436, 1999